Skip to Main Content

Paper Details

Ophthalmic Immune-Related Adverse Events after Anti-CTLA-4 or PD-1 Therapy Recorded in the American Academy of Ophthalmology Intelligent Research in Sight Registry.
Ophthalmology
19
2021
Anti-CTLA-4, PD-1, Patients, anterior uveitis, anti-CTLA-4, anti-PD-1, autoimmune ocular disease, cancer, ipilimumab, nivolumab, ocular inflammation, ocular inflammatory condition, ophthalmic immune-related AE, papilledema, patients, pembrolizumab, programmed cell death 1, uveitis
Author NameAffiliation
Gary N HollandStein Eye Institute, David Geffen School of Medicine at the University of California at Los Angeles
Flora LumAmerican Academy of Ophthalmology
Lynn K GordonStein Eye Institute, David Geffen School of Medicine at the University of California at Los Angeles
  • 1 - 3

Datasets

Release 1.2